Specifically Matching Targeted Therapy to Patients' Tumors Shows Benefit, Even in Early Studies
Richard L. Schilsky, MD, Past ASCO President, Professor of Medicine and Chief, Section of Hematology-Oncology, University of Chicago Pritzker School of Medicine, and Deputy Director, Comprehensive Cancer Center, University of Chicago.
In this study, researchers looked at the tumors from 1,144 patients with advanced cancer to find specific changes to the tumor’s genes, called mutations. The tumors from 460 patients had one or more genetic mutations. Each of these patients received a targeted therapy drug that targets the specific genetic mutation found in their tumor.
|NeonCRM by Neon One|